Inhibitor/Activator
| Cat.No. | Name | Information |
|---|---|---|
| M2328 | Pirfenidone | Pirfenidone inhibits TGF-β bioactivity by affecting TGF-β2 mRNA expression and processing of pro-TGF-β in CCL-64 cells. Pirfenidone (AMR69) attenuates CCL2 and CCL12 production in fibrocyte cells. |
| M9083 | Disitertide | Disitertide is a TGF-β1 inhibitor. |
| M4863 | Kartogenin | Kartogenin is an activator of the smad4/smad5 pathway, and promotes the selective differentiation of multipotent mesenchymal stem cells into chondrocytes. |
| M50389 | H-Leu-Ser-Lys-Leu-OH | H-Leu-Ser-Lys-Leu-OH (LSYL) is a latency-associated peptide at the amino terminus of LAP, with inhibitory effect on TGF-β1 activation. |
| M49789 | SY-LB-35 | SY-LB-35 is a potent bone morphogenetic protein (BMP) receptor agonist. |
| M43560 | DT-6 | DT-6 is an effective TGF-β1 inhibitor. |
| M39853 | Dalbergioidin | Dalbergioidin, a well-known anthocyanin, ameliorates doxorubicin-induced renal fibrosis by suppressing the TGF-β signal pathway. Dalbergioidin exhibits tyrosinase inhibitory activity with an IC50 of 20 mM. |
| M31363 | YH14618 | YH14618 is a synthetic peptide that is also a TGF-β1 modulator and can be used in studies related to disc degenerative diseases. |
| M25377 | Nadecnemab | Nadecnemab is an IgG4κ antibody targeting to GFRA3, glial cell derived neurotrophic factor family receptor alpha 3. Nadecnemab can be used for research of osteoarthritis of the knee/pain. |
| M25307 | Fresolimumab | Fresolimumab (GC1008) is a high-affinity fully human monoclonal antibody that neutralizes the active form of human TGFβ1, TGFβ2, and TGFβ3. Fresolimumab can be used for the research of cancer and fibrotic diseases . |
| M25249 | Stamulumab | Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research. |
| M25204 | Lerdelimumab | Lerdelimumab (CAT-152) is an IgG4 human anti-TGF-β2 recombinant monoclonal antibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research. |
| M25202 | Metelimumab | Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that can selectively neutralize TGFβ1. |
| M25175 | Cirevetmab | Cirevetmab (ZTS-00521426) is an immunoglobulin G2-kappa, Canis lupus familiaris TGFB1 caninized monoclonal antibody. Cirevetmab is an immunomodulator. |
| M25124 | Livmoniplimab | Livmoniplimab (ABBV-151; ARGX-115) is a potent humanized anti-LRRC32 (GARP)/TGFβ1 monoclonal antibody. Livmoniplimab blocks LRRC32-mediated activation of latent TGFβ1. Livmoniplimab has the potential for the research of cancer. |
| M24914 | Garetosmab | Garetosmab (REGN 2477) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans progressiva (FOP) research. |
| M24850 | Bintrafusp alfa | Bintrafusp alfa (M 7824) is a first-in-class bifunctional fusion protein composed of the extracellular domain of TGF-βRII fused to a human IgG1 mAb blocking programmed cell death ligand. Bintrafusp alfa can be used for the research of cancer. |
| M24799 | Elezanumab | Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism. |
| M24634 | Luspatercept | Luspatercept (ACE-536) is a first-in-class recombinant modified ActRIIB fusion protein that binds with transforming growth factor β superfamily ligands. Luspatercept increases the erythrocyte numbers and promotes maturation of erythroid precursors. Luspatercept binds with GDF11 and inhibits Smad2/3 signaling. Luspatercept can be used for the research of anemia. |
| M24597 | Carotuximab | Carotuximab (TRC105) is a IgG1 monoclonal antibody that blocks endoglin (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antineoplastic actions. |
| M24570 | Dalantercept | Dalantercept (ACE-041) is an activin receptor like kinase 1 (ALK1) inhibitor, a ligand trap for bone morphogenetic proteins (BMP) 9 and BMP 10. Dalantercept reduces tumor angiogenesis and delays tumor growth by binding to BMP 9 and BMP 10. As an anti angiogenic agent, Dalantercept has potential applications in persistent or recurrent ovarian cancer, renal cell carcinoma (RCC), and related malignant tumors. |
| M24561 | Ramatercept | Ramatercept is a soluble ActRIIB receptor and can be used as a soluble activin receptor 2 (ACVR2) antagonist. Ramatercept inhibits the signal pathway of muscle growth inhibition and has potential application in muscle atrophy. |
| M22478 | Zilurgisertib | Zilurgisertib is a selective ALK2 inhibitor. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
